CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1141-1147

  Torti, Carlo ^a   Lapadula, Giuseppe ^a   Barreiro, Pablo ^b   Soriano, Vicente ^b   Mandalia, Sundhiya ^c   De Silvestri, Annalisa ^d   Suter, Fredy ^e   Maggiolo, Franco ^e   Antinori, Andrea ^f   Antonucci, Francesco ^f   Maserati, Renato ^d   El Hamad, Issa ^a   Pierotti, Piera ^g   Sighinolfi, Laura ^h   Migliorino, Guglielmo ⁱ   Ladisa, Nicoletta ^j   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^h SANT ANNA HOSPITAL   (Italy)

ⁱ OSPEDALE DI CIRCOLO   (Italy)

^j POLICLINICO   (Italy)

more..

Author keywords

Antiretroviral therapy; CD4 cell count; Immune recovery; Immune toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; DIDANOSINE; HEPATITIS C ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTION; REGRESSION ANALYSIS; STATISTICAL MODEL; TREATMENT DURATION; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RISK FACTORS; SEX CHARACTERISTICS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34447572755     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm100     Document Type: Article

References (23)

1. Barrios A, Rendon A, Negredo, E et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19: 569-75.
2. Lacombe K, Pacanowski J, Meynard JL et al. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. AIDS 2005; 19: 1107-8.
3. Negredo E, Molto J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofavir-based regimens despite undetectable viral load. AIDS 2004; 18: 459-63.
4. Barrios A, Negredo E, Domingo P et al. Simplification therapy with once-daily didanosine, tenotovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Antivir Ther 2005; 10: 825-32.
5. Barreiro P, Soriano V Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57: 806-9.
6. Negredo E, Bonjoch A, Paredes R et al. Compromised immunologic recovery in treatment-experienced patents with HIV infection receiving both tenofavir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis 2005; 41: 901-5.
7. Karrer U, Ledergerber B, Furrer H et al. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS 2005; 19: 1987-94.
8. Leon A, Martinez E, Mallolas J et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19: 213-5.
9. Maitland D, Moyle G, Hand J et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19: 1183-8.
10. Podzamczer D, Ferrer E, Gatell JM et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10: 171-7.
11. Torti C, Quiros-Roldon E, Regazzi M et al. Early virological failure after tenofovir+didanosine+efavirenz combination in HIV-positive patients upon starting antiretrovirall therapy. Antivir Ther 2005; 10: 505-13.
12. Di Biagio A, Beltrame A, Cenderello G et al. Clinically stable treatment-experienced adults receiving tenofovir and didanosine. HIV Clin Trials 2006; 7: 10-5.
13. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006; 57: 4-7.
14. Bryl E, Witkowski JM. Decreased proliferative capability of CD4+ cells of elderly people is associated with faster loss of activation-related antigens and accumulation of regulatory T cells. Exp Gerontol 2004; 39: 587-95.
15. Dennett NS, Barcia RN, McLeod JD. Age associated decline in CD25 and CD28 expression correlate with an increased susceptibility to CD95 mediated apoptosis in T cells. Exp Gerontol 2002; 37: 271-83.
16. Donnini A, Re F, Bollettini M et al. Age-related susceptibility of naive and memory CD4 T cells to apoptosis induced by IL-2 deprivation or PHA addition. Biogerontology 2005; 6: 193-204.
17. Nunez M, Soriano V, Lopez M et al. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis 2006; 43: 1209-12.
18. Litjens NH, van Druningen CJ, Betjes MG Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 2006; 118:83-91.
19. Leon A, Mallolas J, Martinez E et al. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. AIDS 2005; 19: 1695-7.
20. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 10 October 2006. Http://AIDSinfo.nih.gov.
21. Kirian MA, Higginson RT, Fulco PP. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother 2004; 38:1660-3.
22. Masia M, Gutierrez F, Padilla S et al. Severe toxicity associated with the combination of tenofovir and didanosine: Case report and review. Int J STD AIDS 2005; 16: 646-8.
23. Cote HC, Magil AB, Harris M et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11: 79-86.